Genentech's ACTEMRA(r) Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab Monotherapy

March 2012
Biomedical Market Newsletter;3/7/2012, Vol. 21, p1
The article presents information on the ADACTA (ADalimumab ACTemrA) study according to which patients receiving ACTEMRA® (tocilizumab) experienced more decrease in disease activity after 24 weeks than those who were given adalimumab monotherapy. It is further mentioned that ADACTA study compares ACTEMRA and adalimumab for the treatment of patients with rheumatoid arthritis that are intolerant to methotrexate (MTX) .


Related Articles

  • Is three selected parameters adequate to monitor rheumatoid arthritis? Chandrashekara, S.; Syed, M.; Swapna, R. // Clinical Rheumatology;Jun2007, Vol. 26 Issue 6, p911 

    This pilot study was done to choose which among the five core set criteria will have more discriminating ability and which is easy to administer in a clinical setting. Forty-eight patients recently diagnosed to have rheumatoid arthritis (RA) were recruited for the study. They were assessed by a...

  • Head-to-head study with RA drugs.  // Australian Journal of Pharmacy;Jul2013, Vol. 94 Issue 1118, p30 

    The article focuses on the study ADalimumab ACTemrA (ADACTA)", which was published in the periodical "The Lancet," reveals that Actemra offers improvement in the signs and symptoms of rheumatoid arthritis (RA) for patients who require monotherapy as compared to adalimumab, as of July 1, 2013.

  • Minus the tough stuff. Munson, Marty // Prevention;Mar96, Vol. 48 Issue 3, p54 

    Offers a sign of relief for rheumatoid arthritis patients in that they may be able to cut down on medication and thus cut back on adverse effects from those medications. Study of patients on methotrexate by the division of rheumatology at Albany Medical College, New York; Details of the study...

  • Methotrexate Treatment of Rheumatoid Arthritis. Willkens, Robert F. // Annals of Internal Medicine;Oct85, Vol. 103 Issue 4, p612 

    Editorial. Deals with the effectiveness of methotrexate treatment of rheumatoid arthritis. Limited toxicity of the drug; Long-term dermatologic effect of the methotrexate; Other agents used for the treatment of rheumatoid arthritis.

  • Chelsea Therapeutics Reports on Phase II CH-4051.  // Biotech Business;Jul2012, Vol. 25 Issue 7, p5 

    The article reports on the Phase 2 trial that compares the efficacy and tolerability of the non-metabolized antifolate clinical trial drug, CH-4051, against antimetabolite and antifolate drug methotrexate in patients with rheumatoid arthritis. According to biopharmaceutical company Chelsea...

  • TAKING ON 'TiGER.'. Pisetsky, David S. // Arthritis Today;May/Jun2002, Vol. 16 Issue 3, p38 

    Presents the case of a patient with severe rheumatoid arthritis (RA). Treatment given to the patient prior to the clinical trial; Description of a clinical trial involving the methotrexate treatment of a patient with RA; Response of the patient to the drug.

  • Review: The addition of infliximab and etanercept to methotrexate is effective in the long term for rheumatoid arthritis.  // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p42 

    The article presents information on a research that suggested that addition of infliximab (IFX) to methotrexate reduced symptoms and drug discontinuation in patients with rheumatoid arthritis (RA) in the long term. It is stated that etanercept (ETN) or IFX was compared in 30 patients with RA in...

  • Methotrexate.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p195 

    An abstract of the article "Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report" by H. Shimada and others is presented.

  • Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis. Rakieh, Chadi; Conaghan, Philip G. // Therapeutics & Clinical Risk Management;2014, Vol. 10, p313 

    Biologic therapies in rheumatoid arthritis are now part of standard practice for disease that proves difficult to control with conventional disease-modifying anti-rheumatic drugs. While anti-tumor necrosis factor therapies have been commonly used, other targeted biologic therapies with different...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics